- Home
- RLTY vs TLSI Comparison
RLTY vs TLSI Comparison
Compare RLTY & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RLTY | TLSI |
|---|---|---|
| Founded | 2022 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 262.5M | 250.0M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RLTY | TLSI |
|---|---|---|
| Price | $13.80 | $3.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $10.40 |
| AVG Volume (30 Days) | 76.2K | ★ 318.4K |
| Earning Date | 01-01-0001 | 11-12-2026 |
| Dividend Yield | ★ 9.35% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $45,151,000.00 |
| Revenue This Year | N/A | $17.65 |
| Revenue Next Year | N/A | $40.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 53.41 |
| 52 Week Low | $13.34 | $2.20 |
| 52 Week High | $16.41 | $7.95 |
Technical Indicators
Market Signals| Indicator | RLTY | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 39.58 | 25.81 |
| Support Level | $13.34 | $3.05 |
| Resistance Level | $15.92 | $3.68 |
| Average True Range (ATR) | 0.22 | 0.25 |
| MACD | 0.06 | -0.05 |
| Stochastic Oscillator | 61.06 | 4.08 |
Price Performance
Historical ComparisonAbout RLTY Cohen & Steers Real Estate Opportunities and Income Fund of Beneficial Interest
Cohen & Steers Real Estate Opportunities and Income Fund is a non-diversified, closed-end management statutory trust. Its primary investment objective is high current income. Its secondary investment objective is capital appreciation. The fund invests the majority of its managed assets in real estate-related investments and preferred and other income securities.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.